![Androgen and glucocorticoid receptor domain organisation.\
A hypothetical structural model for the full-length AR and GR based on structural information for the isolated ligand-binding (LBD) and DNA-binding (DBD) domains is shown. Note: high resolution structures are available for the isolated LBD and DBD of nearly all SHR, but no multi-domain structure has yet been reported for a member of the nuclear receptor superfamily. The LBD consists of 12 α-helices folded in a three-layer helical sandwich and is linked via a flexible hinge region to the DBD, which has a characteristic globular fold made up of two perpendicular α-helices. The NTD is unique to each SHR and has variable sequence and length \[Lavery and McEwan, 2005\]. The proposed helical and unfolded conformation for this domain is based in structure predictions (see below), spectroscopy analysis and site-directed mutagenesis and proteolytic sensitivity of the AR- and GR-NTD (see text for details).](nrs05001.f1){#fig1}

![Consensus secondary structure and disorder predictions for AR-NTD and GR-NTD.\
(A) and (B) Consensus secondary structure \[Combet et al., 2000\] and disorder predictions (Glob plot: Linding et al., 2003) for the AR-NTD and GR-NTD, respectively. The location of AF1 is shown above the secondary structure plot (blue and red bars represent α-helix and β-strand structure, respectively) for AR and GR. In addition the four putative helical regions in AR-AF1 are indicated (A, I-IV) and the location of three helices observed in the GR-AF1 core (B) are highlighted.](nrs05001.f2){#fig2}

![SHR-NTD: regions of intrinsic structural disorder.\
The amino acid compositional bias for regions within the SHR-NTD is shown. Small (Ala, Gly), uncharged hydrophilic (Asn, Gln, Ser, Thr) and proline residues (Green shading); charged residues (Red and Blue shading); and hydrophobic residues (Yellow shading). Androgen Receptor, amino acids 1 to 558; Glucocorticoid Receptor, amino acids 1 to 420; Progesterone Receptor, amino acids 1 to 566; Mineralocorticoid Receptor, amino acids 1 to 602; Estrogen Receptor α, amino acids 1 to 184 and β, amino acids 1 to 148. Amino acid numbering and sequences are for the human receptors.](nrs05001.f3){#fig3}

Introduction
============

Steroid hormone receptors (SHR) are intracellular proteins that regulate patterns of gene expression in target tissues in response to small lipophilic hormones synthesised from cholesterol. They are important for normal development, reproductive function and the regulation of metabolism and salt balance. The receptor proteins have a well-defined domain organisation and high-resolution structures are available for the C-terminal ligand binding domain (LBD), with different agonist and antagonist ligands bound, and the zinc-finger DNA-binding domain (DBD) ([Figure 1](#fig1){ref-type="fig"}). SHR have been shown to contain two transactivation functions: one is represented by a structurally defined hydrophobic groove on the surface of the LBD, formed by residues from helices 3, 4, 5 and 12 (AF2), while the other maps to the structurally flexible N-terminal domain (NTD) and is termed AF1 ([Figure 1](#fig1){ref-type="fig"}). The main determinants for transactivation map to NTD of both the androgen (AR) and glucocorticoid (GR) receptors ([Figure 2](#fig2){ref-type="fig"}A and reviewed in \[[@r28]\]) and while generally there is little sequence conservation between the different SHR-NTDs, in contrast to the DBD and LBD, short regions of similarity have been observed for the AR and GR. For example, a four amino acid synergy control motif \[[@r22]\], a hydrophobic signature sequence implicated in transactivation \[[@r5]\] and a 26 amino acid sequence, that is located within the AF1 domain, that shows 46% amino acid identity between AR (amino acids 237 to 262) and GR (amino acids 47 to 103) (IJM unpublished observation). The NTD is potentially involved in multiple protein-protein interactions \[[@r28]\] and the length of this domain has been positively correlated with the activity of AF1 for different members of the nuclear receptor superfamily \[[@r17]\].

Androgen receptor-NTD (NR3C4)
=============================

Folding and function
--------------------

The AR-NTD transactivation function is highly modular, with key sequences mapping to amino acids 101 to 370 and 360 to 485 and termed TAU1 and TAU5, respectively \[[@r7]; [@r23]; [@r36]\]. A fusion protein containing amino acids 142 to 485 (human AR), consisting of most of TAU1 and all of TAU5, retained about 70% of the activity of the full-length NTD when measured in yeast cells *in vivo* \[[@r33]\] and also activated a reporter gene *in vitro*, when fused to a heterologous DBD \[[@r8]; [@r31]\].

The first 25 amino acids of the AR-NTD contain a FxxLF motif, that forms part of an amphipathic α-helix (residues 21 to 30) and interacts with the AR-LBD (AF2) \[[@r17]; [@r18]\]. Predictions of disordered structure suggest this region is globular ([Figure 2](#fig2){ref-type="fig"}A) and recent structural studies comparing the binding of peptides containing either an FxxLF or an LxxLL motif revealed that the AR-NTD peptide forms a charge clamp with glutamic acid 897 in helix 12 and lysine 720 at the end of helix 3, and the more bulky hydrophobic residues fit better into the surface pocket of AF2 \[[@r17]; [@r20]\]. In contrast, a LxxLL motif peptide fails to make hydrogen bond contacts with the glutamic acid residue in helix 12 and makes fewer hydrophobic contacts with the surface of the LBD \[[@r17]; [@r20]\]. Interestingly, while other SHR interact with coactivator proteins via LxxLL motifs, which bind in the hydrophobic groove of AF2, the AR-LBD preferentially binds the AR-NTD and coactivators with more bulky hydrophobic residues in the sequence F/WxxLF/W/Y \[[@r18]; [@r19]\], which may explain the relatively weak activity observed for AR-AF2.

The AR-AF1 (amino acids 142 to 485) is predicted to be highly disordered and has limited structure, as revealed by circular dichroism and fluorescence spectroscopy, which is lost upon urea-induced unfolding ([Figure 2](#fig2){ref-type="fig"}A and \[[@r32]\]). In contrast, incubation with the natural organic osmolyte, trimethylamine-N oxide (TMAO), or the hydrophobic solvent trifluoroethanol (TFE) induces and/or stabilises a more folded conformation in the AF1 domain. This folding of AF1 is associated with a more protease resistant conformation and is concomitant with a significant increase in α-helical content of AR-AF1 (13-16% to 37-40%), at the expense of both non-ordered and β-structure \[[@r25]; [@r32]\]. Significantly, this more folded helical conformation is induced upon binding the AR target factor TFIIF, which in turn appears to create a platform for further protein-protein interactions \[[@r25]; [@r32]\].

Mutations affecting the structure-function of the AR-NTD
--------------------------------------------------------

We initially predicated four helical segments within AR-AF1, which could be disrupted under native conditions by the introduction of proline residues: helix I, amino acids 175 to 201; helix II, 231 to 252; helix III, 341 to 358; and helix IV, 393 to 411 ([Figure 2](#fig2){ref-type="fig"}A: I-IV) \[[@r32]\]. A 14 amino acid sequence in the first of these regions was previously shown to be important for AF1 activity and predicated to form an amphipathic α-helix \[[@r7]\]. Recently, residues in this region were found to act as a docking site for TAB2, a component of the N-CoR corepressor complex, which acts as a sensor molecule for androgen, estrogen and cytokine signalling pathways \[[@r39]\].

When the AR-NTD sequences from at least twelve different species were compared, three highly conserved regions were identified: amino acids 1 to 30, 224 to 258 and 500 to 541 \[[@r5]\]. The second of these sequences includes helical region II identified in the AF1 domain (see above and [Figure 2](#fig2){ref-type="fig"}A) and mutation of conserved hydrophobic residues reduced transactivation activity, but had minimal, if any effect, on conformation as determined by fluorescence spectroscopy and limited proteolysis \[[@r5]\]. Interestingly, two mutations A234T and E236G, originally identified in a mouse model for prostate cancer, also map to this sequence \[[@r15]; [@r16]\]. Structure predictions suggest no dramatic changes in secondary structure for the A234T change, but the possible increase in an adjacent β-strand structure for the E234G mutation (IJM unpublished observations). In recent molecular dynamic simulations these mutations were suggested to stabilize the predicted helical conformation \[[@r15]\]. Garabedian and co-workers reported on a third mutation identified in a patient with prostate cancer, P340L, which may also have altered structural properties \[[@r29]\]. This mutation is predicted to disrupt local secondary structure (IJM unpublished observations) and to alter folding of α-helices in the region of amino acids 331 to 355 \[[@r29]\]. Interestingly, these mutations have been shown to alter different protein-protein interactions with coregulatory proteins: A234T and E236G reduced the binding of the chaperone protein CHIP \[[@r16]\], while P340L enhanced the binding of the AR coregulatory protein ART-27 \[[@r29]\]. Intriguing structural and functional changes were also observed when a double point mutation was introduced into a six amino acid repeat sequence in AF1, ^158^PSTLSL^163^ (serine to alanine). These changes disrupted binding of TFIIF \[[@r33]\] and resulted in a more folded conformation for AF1 \[[@r5]\]. Thus, taken together these findings describe two classes of mutation in the AR-NTD: the first have been shown and/or predicted to alter the conformational flexibility of this domain and receptor activity, while the second group alter function without apparently disrupting structure. To date, about a third of the single point mutations identified in clinical samples of prostate cancer map to the AR-NTD \[[@r35]\]. Overall, the structure-function studies of the AR-NTD/AF1 have emphasised a dynamic interplay between protein folding and conformation and receptor function, which may be further modulated by clinically relevant point mutations.

Glucocorticoid receptor-NTD (NR3C1); folding and function
=========================================================

The AF1 function of the GR was initially mapped to amino acids 77 to 262 for the human receptor. Subsequently, a 58 amino acid core function was delineated to amino acids 187 to 244 (Reviewed in \[[@r28]\]). Mutations altering hydrophobicity or the acidic character of both the human and rat GR transactivation domains were found to impair transactivation activity \[[@r1]; [@r2]; [@r21]\]. This suggests that such residues are important structurally and/or formed surfaces involved in protein-protein interactions. Recently, a study combining mutations in the GR AF1 or AF2 domains with gene array analysis revealed a differential requirement for the NTD (AF1) and LBD (AF2) transactivation functions \[[@r34]\], emphasising a potential additional level of selectivity in SHR signalling.

[Figure 2](#fig2){ref-type="fig"}B shows the predictions for secondary structure and regions of disordered structure within the GR-NTD and suggests significant disorder within the AF1 domain and the region N-terminal to the DBD. Folding of the GR-AF1 (amino acids 77 to 262) or AF1 core (amino acids 187 to 244) domain into a more stable helical conformation has been observed in the presence of both the solvent TFE and the natural solute TMAO. Using NMR spectroscopy, Dahlman-Wright and co-workers originally described three helical segments within the AF1 core, in the presence of 40% TFE: amino acids 189 to 200, 216 to 226 and 235 to 241 ([Figure 2](#fig2){ref-type="fig"}B and \[[@r11]\]). Introduction of helix-breaking proline mutations resulted in disruption to both secondary structure and transactivation potential \[[@r12]\]. A subsequent study by Thompson and Kumar and co-workers showed changes in tryptophan fluorescence emission spectra in the presence of TMAO and upon DNA binding, indicative of structural changes within the GR-NTD \[[@r4]\]. Folding of the NTD was also shown to enhance the binding of the coregulatory target proteins TBP, CBP and the p160 family member SRC-2 (GRIP1) \[[@r26]\]. More recently, these authors showed the binding of TBP to GR-AF1 occurred *in vivo* and induced a coil to α-helix transition with concomitant alterations in the chemical shifts of four glycine residues present in the GR-AF1 core region *in vitro* \[[@r10]; [@r27]\]. Therefore, similar to the AR, the GR-AF1 appears structurally flexible and has the propensity to form an α-helical conformation. In addition to the above studies on AR and GR, Warnmark et al (2001) found that the NTD of estrogen receptor (ER) α and β were unstructured when studied by both NMR and circular dichroism spectroscopy. Significantly, the ERα, but not ERβ, -NTD adopted a more structured conformation upon binding the general transcription factor the TATA-binding protein \[[@r37]\]. Thus, in spite of the lack of high resolution structural data, a large body of evidence now exists underlining an induced structure model for both the AR and GR AF1 domains upon specific DNA and/or protein binding.

Natural disordered sequences and the SHR-NTD
============================================

What is the nature of this structural flexibility? The concept of regions or even whole domains of proteins being naturally disordered has gained much attention recently as more evidence accumulates to support the hypothesis that such sequences are (i) very common in eukaryotic proteins and (ii) functionally important \[[@r13]; [@r14]\]. Intrinsically unstructured regions have been implicated in molecular recognition and assembly of protein complexes and as sites of post-translational modification \[[@r13]; [@r14]\]. Thus, a consideration of natural disordered sequences within steroid receptor-NTDs is highly appropriate given the available structural information, the function of this domain in multiple protein-protein interactions and as a target for post-translational modifications (phosphorylation and sumoylation) (Reviewed in \[[@r28]\]). While lacking any significant level of primary sequence homology, analysis of the amino acid composition of SHR-NTDs suggests some shared structural properties. The presence of a high proportion of proline, serine and glycine residues in the NTDs of steroid receptors conforms to the amino acid compositional bias associated with a signature for intrinsic disorder \[[@r14]\]. [Figure 3](#fig3){ref-type="fig"} shows an analysis of the primary amino acid sequence of the NTD for the six major steroid receptors, with amino acids colour coded depending on the properties of their side-chains. It is clear there are large stretches of potentially disordered structure with a compositional bias towards small (Ala, Gly), uncharged hydrophilic (Asn, Gln, Ser, Thr) and proline residues (Green shading). Interspersed are sequences of charged (Red and Blue shading) and hydrophobic (Yellow shading) residues, which may represent interaction sites for protein-protein interactions and/or more structured regions. A recent analysis \[[@r28]\] of individual SHR-NTDs using the trained neural network programme PONDR® and the GlobPlot predictions for the AR and GR-NTDs ([Figure 2](#fig2){ref-type="fig"}A and [Figure 2](#fig2){ref-type="fig"}B) supports the view that these domains contain significant levels of intrinsically disordered structure and is in good general agreement with the amino acid compositional bias profiling shown in [Figure 3](#fig3){ref-type="fig"}. There is also good general agreement correlating potential regions of naturally disordered structure with sequences identified as playing a role in the control of gene expression for the different SHR. Thus, structural flexibility is likely to result from the amino acid compositional bias and underpin the ability of SHR-NTD to make multiple protein-protein interactions with the cellular transcription machinery.

Conclusions and future perspectives
===================================

Specificity in SHR signalling is exerted at a number of key steps, notably the binding of hormone and subsequent recognition and binding to DNA response elements. While the structural basis of both hormone and DNA binding specificity are generally well described, the structural basis for AF1 activity, located in the distinct NTD, is only now beginning to be revealed. Extensive analysis of the isolated AR and GR AF1 domains emphasises the structural plasticity of this domain and the importance of flexibility for receptor function. An important question is what is the conformation of the NTD in the context of the full-length SHR? From the available experimental evidence two possible models can be proposed for SHR-NTD structure: in the first the NTD exists in an equilibrium of essentially non-ordered, random-coil conformers, while in the second, the NTD would exhibit limited structural stability consisting of regions of disorder and variable levels of secondary structure. The latter is a particularly attractive model, with the NTD in a flux of partially folded intermediate structures that collapse into a stable structure upon protein-protein interactions. In both models it seems likely that the NTD structure will be stabilised, at least partially by intramolecular interactions with the DBD and/or LBD. Indeed, studies with two domain constructs of the AR \[[@r6]\], GR \[[@r24]\], progesterone receptor \[[@r3]\] and the full-length ER \[[@r38]\] suggest that the presence of the DBD and/or specific DNA binding leads to structural changes in the NTD. Therefore, both intra- and inter-molecular interactions will result in an induction and/or stabilisation of a more folded, active conformation in the SHR-NTD. Future analysis will have to consider whether different conformations are induced in the NTD depending on DNA response element and/or target protein binding, and also the role played by post-translational modifications (i.e. phosphorylation), which are likely to lead to additional levels of complexity and potential specificity in SHR action. Furthermore, as studies have revealed that both active and non-productive conformations may be stabilised for the AR-NTD, it is reasonable to propose that folding of SHR-NTD may serve as a future target for drug discovery for the treatment of conditions ranging from cancer to neurodegeneration.
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